JSAM
WST icon

J. Safra Asset Management’s West Pharmaceutical WST Stock Holding History

J. Safra Asset Management’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2
Closed -$448 – 401
2025
Q1 		$448 Buy
+2
New +$551 ﹤0.01% 342

Other funds holding WST

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
APG Asset Management
APG Asset Management Amsterdam, Netherlands $31.6B AUM 19.33% 1-Year Est. Return

J. Safra Asset Management's WST Position: Q2 2025 in Review

J. Safra Asset Management sold out of West Pharmaceutical (WST) in Q2 2025, closing a stake of 2 shares — an estimated $448 sold.

J. Safra Asset Management first reported a position in WST in Q1 2025 and held it in 1 quarter. The position peaked at $448 in Q1 2025. 730 funds tracked by Wall St. Rank hold WST as of Q2 2025.

  • J. Safra Asset Management reported no remaining West Pharmaceutical position as of Q2 2025 after selling out during the quarter.
  • J. Safra Asset Management sold 2 West Pharmaceutical shares in Q2 2025, an estimated $448.
  • J. Safra Asset Management first reported a position in West Pharmaceutical in Q1 2025 and held it in 1 quarter.
  • J. Safra Asset Management's West Pharmaceutical position peaked at $448 in Q1 2025.
  • 730 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2025.

Based on J. Safra Asset Management's 13F filing for Q2 2025, filed 28 Jul 2025.